A detailed history of Northern Trust Corp transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,389,041 shares of LYEL stock, worth $2.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,389,041
Previous 1,441,970 3.67%
Holding current value
$2.1 Million
Previous $3.22 Million 37.36%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.3 - $3.01 $68,807 - $159,316
-52,929 Reduced 3.67%
1,389,041 $2.01 Million
Q1 2024

May 14, 2024

SELL
$1.71 - $3.07 $57,351 - $102,964
-33,539 Reduced 2.27%
1,441,970 $3.22 Million
Q4 2023

Feb 13, 2024

SELL
$1.39 - $2.35 $10,659 - $18,022
-7,669 Reduced 0.52%
1,475,509 $2.86 Million
Q3 2023

Nov 13, 2023

BUY
$1.45 - $3.35 $70,932 - $163,878
48,919 Added 3.41%
1,483,178 $2.18 Million
Q2 2023

Aug 11, 2023

SELL
$1.89 - $3.86 $560,417 - $1.14 Million
-296,517 Reduced 17.13%
1,434,259 $4.56 Million
Q1 2023

May 15, 2023

SELL
$1.97 - $3.58 $901,793 - $1.64 Million
-457,763 Reduced 20.92%
1,730,776 $4.08 Million
Q4 2022

Feb 13, 2023

BUY
$2.78 - $8.09 $416,505 - $1.21 Million
149,822 Added 7.35%
2,188,539 $7.59 Million
Q3 2022

Nov 14, 2022

BUY
$5.54 - $8.27 $4.62 Million - $6.9 Million
834,445 Added 69.29%
2,038,717 $14.9 Million
Q2 2022

Aug 12, 2022

BUY
$3.68 - $6.8 $558,852 - $1.03 Million
151,862 Added 14.43%
1,204,272 $7.85 Million
Q1 2022

May 13, 2022

BUY
$5.05 - $7.7 $4.25 Million - $6.47 Million
840,833 Added 397.41%
1,052,410 $5.32 Million
Q4 2021

Feb 08, 2022

SELL
$7.13 - $15.19 $16,163 - $34,435
-2,267 Reduced 1.06%
211,577 $1.64 Million
Q3 2021

Nov 15, 2021

BUY
$11.0 - $17.95 $2.35 Million - $3.84 Million
213,844 New
213,844 $3.17 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $374M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.